ZA200902540B - Immunization protocol against the 4 dengue serotypes - Google Patents

Immunization protocol against the 4 dengue serotypes

Info

Publication number
ZA200902540B
ZA200902540B ZA200902540A ZA200902540A ZA200902540B ZA 200902540 B ZA200902540 B ZA 200902540B ZA 200902540 A ZA200902540 A ZA 200902540A ZA 200902540 A ZA200902540 A ZA 200902540A ZA 200902540 B ZA200902540 B ZA 200902540B
Authority
ZA
South Africa
Prior art keywords
immunization protocol
dengue serotypes
protocol against
serotypes
dengue
Prior art date
Application number
ZA200902540A
Other languages
English (en)
Inventor
Bruno Guy
Veronique Forrat Remi Barban
Jean Lang
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of ZA200902540B publication Critical patent/ZA200902540B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200902540A 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes ZA200902540B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (1)

Publication Number Publication Date
ZA200902540B true ZA200902540B (en) 2010-07-28

Family

ID=38198298

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902540A ZA200902540B (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes

Country Status (16)

Country Link
US (2) US7718359B2 (cg-RX-API-DMAC7.html)
EP (1) EP2099483B1 (cg-RX-API-DMAC7.html)
JP (1) JP5269803B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090087890A (cg-RX-API-DMAC7.html)
CN (1) CN101541344A (cg-RX-API-DMAC7.html)
AR (1) AR064009A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007327367B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718927A2 (cg-RX-API-DMAC7.html)
CA (1) CA2668570A1 (cg-RX-API-DMAC7.html)
FR (1) FR2909286B1 (cg-RX-API-DMAC7.html)
IL (2) IL198466A (cg-RX-API-DMAC7.html)
MX (1) MX2009004223A (cg-RX-API-DMAC7.html)
MY (1) MY180698A (cg-RX-API-DMAC7.html)
TW (1) TWI400249B (cg-RX-API-DMAC7.html)
WO (1) WO2008065315A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200902540B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
MX343172B (es) * 2009-06-01 2016-10-26 Takeda Vaccines Inc Composiciones y metodos para administracion de vacunas contra virus del dengue.
AU2010286368B2 (en) * 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8920813B2 (en) 2010-12-20 2014-12-30 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
US20150196631A1 (en) 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
PE20150356A1 (es) 2012-07-24 2015-03-20 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
EP3691681A1 (en) 2017-10-05 2020-08-12 Sanofi Pasteur Compositions for booster vaccination against dengu
PE20211545A1 (es) 2018-09-05 2021-08-16 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administracion de esta
CN114555113A (zh) 2019-08-16 2022-05-27 武田疫苗股份有限公司 用于预防登革热和甲型肝炎的方法
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
WO2000057910A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
ES2322327T3 (es) * 1999-03-26 2009-06-19 Walter Reed Army Institute Of Research Vacuna multivalente contra el virus del dengue.
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1263965B1 (en) * 2000-02-16 2011-09-28 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
DK1159968T3 (da) * 2000-05-30 2009-02-23 Univ Mahidol Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
BRPI0408774A (pt) * 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
ATE475706T1 (de) * 2005-06-17 2010-08-15 Sanofi Pasteur Abgeschwächter dengue-serotyp-2-stamm
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AR061197A1 (es) * 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.

Also Published As

Publication number Publication date
US7718359B2 (en) 2010-05-18
CN101541344A (zh) 2009-09-23
FR2909286A1 (fr) 2008-06-06
AU2007327367B2 (en) 2013-05-09
MX2009004223A (es) 2009-04-30
IL230052A0 (en) 2014-01-30
JP2010511022A (ja) 2010-04-08
AU2007327367A1 (en) 2008-06-05
TWI400249B (zh) 2013-07-01
TW200829599A (en) 2008-07-16
MY180698A (en) 2020-12-07
EP2099483A1 (fr) 2009-09-16
IL198466A (en) 2014-01-30
EP2099483B1 (fr) 2013-12-25
US20080131460A1 (en) 2008-06-05
CA2668570A1 (en) 2008-06-05
IL198466A0 (en) 2011-08-01
BRPI0718927A2 (pt) 2014-04-08
WO2008065315A1 (fr) 2008-06-05
AR064009A1 (es) 2009-03-04
KR20090087890A (ko) 2009-08-18
JP5269803B2 (ja) 2013-08-21
US20100239612A1 (en) 2010-09-23
FR2909286B1 (fr) 2012-06-08

Similar Documents

Publication Publication Date Title
IL198466A0 (en) Immunization protocol against the 4 dengue serotypes
IL197768A0 (en) Immunisation method against the 4 dengue serotypes
IL196331A0 (en) Method of immunization against the four serotypes of dengue
GB0519871D0 (en) Immunogenic agents
IL194972A0 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-
GB0606655D0 (en) Showerpod 1
PL381338A1 (pl) Kalibrator wytłaczarski
GB0517739D0 (en) Mouth prop
GB0711206D0 (en) Type 114
GB0614920D0 (en) Type 24
GB0614921D0 (en) Type 25
GB0615640D0 (en) Type 25
GB0700856D0 (en) Type hymalaya 07
GB0703806D0 (en) Type 81
GB0615434D0 (en) The letterbox-guv'ner
GB0615051D0 (en) Corcost 1306
GB0604637D0 (en) Corcost 10
GB0602974D0 (en) Moveclick 9
GB0615058D0 (en) Corcost 406
GB0615057D0 (en) Corcost 306
GB0615056D0 (en) Corcost 106
GB0615050D0 (en) Corcost 706
GB0612310D0 (en) Corcost 1506
GB0612239D0 (en) Corcost 106
GB0612198D0 (en) Corcost 406